Potential Pharmacokinetic Interactions of Common Cardiovascular Drugs and Selected European and Latin American Herbal Medicines: A Scoping Review.
Brazil
Europe
cardiovascular
herb–drug interactions
hyperlipidemia
hypertension
Journal
Plants (Basel, Switzerland)
ISSN: 2223-7747
Titre abrégé: Plants (Basel)
Pays: Switzerland
ID NLM: 101596181
Informations de publication
Date de publication:
31 Jan 2023
31 Jan 2023
Historique:
received:
12
11
2022
revised:
17
01
2023
accepted:
20
01
2023
entrez:
11
2
2023
pubmed:
12
2
2023
medline:
12
2
2023
Statut:
epublish
Résumé
Herb-drug interactions are nowadays an important decision factor in many healthcare interventions. Patients with cardiovascular risk factors such as hyperlipidemia and hypertension are usually prescribed long-term treatments. We need more informed decision tools to direct future clinical research and decision making to avoid HDI occurrences in this group. A scoping review was conducted using data from online databases such as PUBMED, the National Library of Medicine, and the electronic Medicines Compendium. Included studies consisted of the reported effects on Phase 1/2 and P-glycoprotein of herbal medicines listed in the medicines agencies of Latin America and Europe and drugs used for cardiovascular conditions (statins, diuretics, beta blockers, calcium channel blockers, and ACE inhibitors). The cross tabulation of the results allowed for finding potential HDI. as per the preclinical data reviewed here, we encourage more clinical research on whether drugs with apparently very low interaction risk, such as pravastatin, nadolol, and nimodipine/nitrendipine, may help prevent HDI when statins, beta blockers, and calcium channel blockers, respectively, are prescribed for long-term treatments.
Sections du résumé
BACKGROUND
BACKGROUND
Herb-drug interactions are nowadays an important decision factor in many healthcare interventions. Patients with cardiovascular risk factors such as hyperlipidemia and hypertension are usually prescribed long-term treatments. We need more informed decision tools to direct future clinical research and decision making to avoid HDI occurrences in this group.
METHODS
METHODS
A scoping review was conducted using data from online databases such as PUBMED, the National Library of Medicine, and the electronic Medicines Compendium. Included studies consisted of the reported effects on Phase 1/2 and P-glycoprotein of herbal medicines listed in the medicines agencies of Latin America and Europe and drugs used for cardiovascular conditions (statins, diuretics, beta blockers, calcium channel blockers, and ACE inhibitors). The cross tabulation of the results allowed for finding potential HDI.
RESULTS AND CONCLUSIONS
CONCLUSIONS
as per the preclinical data reviewed here, we encourage more clinical research on whether drugs with apparently very low interaction risk, such as pravastatin, nadolol, and nimodipine/nitrendipine, may help prevent HDI when statins, beta blockers, and calcium channel blockers, respectively, are prescribed for long-term treatments.
Identifiants
pubmed: 36771707
pii: plants12030623
doi: 10.3390/plants12030623
pmc: PMC9920503
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Cochrane Database Syst Rev. 2012 Nov 14;11:CD002003
pubmed: 23152211
Clin Pharmacol Ther. 2004 Dec;76(6):557-66
pubmed: 15592327
Clin Pharmacokinet. 2003;42(13):1141-60
pubmed: 14531725
Curr Hypertens Rep. 2014 Feb;16(2):414
pubmed: 24407447
Pharmacogenomics. 2009 Jun;10(6):1017-24
pubmed: 19530969
Clin Pharmacol Ther. 2006 Dec;80(6):565-81
pubmed: 17178259
Planta Med. 2012 Sep;78(13):1478-89
pubmed: 22322396
Blood Press. 2012 Jul;21 Suppl 1:3-10
pubmed: 22762301
Eur J Clin Pharmacol. 1983;24(4):453-6
pubmed: 6861860
Integr Blood Press Control. 2014 Dec 09;7:71-82
pubmed: 25525386
Arch Dis Child Educ Pract Ed. 2015 Feb;100(1):37-43
pubmed: 25122157
Br J Pharmacol. 2012 Mar;165(5):1595-608
pubmed: 21913896
Am J Physiol Renal Physiol. 2016 May 1;310(10):F958-71
pubmed: 26911852
Drug Metab Dispos. 2014 Jan;42(1):126-33
pubmed: 24141856
Cancer Prev Res (Phila). 2015 Mar;8(3):181-9
pubmed: 25586902
Biol Pharm Bull. 2017;40(7):1078-1085
pubmed: 28674251
J Clin Pharmacol. 2018 Oct;58 Suppl 10:S10-S25
pubmed: 30248190
Planta Med. 2019 Aug;85(11-12):987-996
pubmed: 31350736
Fundam Clin Pharmacol. 2005 Feb;19(1):117-25
pubmed: 15660968
Front Pharmacol. 2022 Oct 05;13:826395
pubmed: 36278236
J Cardiovasc Pharmacol Ther. 2014 Jan;19(1):5-13
pubmed: 24243991
Clin Pharmacokinet. 2008;47(7):463-74
pubmed: 18563955
Sci Rep. 2014 Oct 10;4:6587
pubmed: 25300360
Pharmacoepidemiol Drug Saf. 2012 May;21(5):494-506
pubmed: 22422642
ISRN Pharmacol. 2013;2013:146579
pubmed: 23476802
Curr Pharm Des. 2015;21(6):806-22
pubmed: 25341854
Pharmacotherapy. 2013 Feb;33(2):210-22
pubmed: 23386599
J Am Coll Cardiol. 2013 Jun 25;61(25):2495-502
pubmed: 23563132
Foods. 2017 Oct 22;6(10):
pubmed: 29065496
Toxicology. 2011 Jul 11;285(1-2):18-24
pubmed: 21459122
J Drug Target. 2006 Jun;14(5):291-300
pubmed: 16882549
Integr Blood Press Control. 2014 Jul 30;7:35-47
pubmed: 25161365
Clin Pharmacokinet. 1998 Jan;34(1):1-24
pubmed: 9474471
Front Pharmacol. 2016 Aug 10;7:248
pubmed: 27559312
Heart Fail Rev. 2012 Mar;17(2):305-11
pubmed: 21516306
Lancet. 2000 Jan 8;355(9198):134-8
pubmed: 10675182
Biochem Pharmacol. 2014 Jan 1;87(1):93-120
pubmed: 24055064
Clin Pharmacol Ther. 2007 May;81(5):679-84
pubmed: 17301736
Ther Adv Drug Saf. 2013 Feb;4(1):5-7
pubmed: 25083246
Front Pharmacol. 2014 Jul 09;5:162
pubmed: 25071580
Bull World Health Organ. 2008 Aug;86(8):594-9
pubmed: 18797616
J Clin Psychopharmacol. 2016 Aug;36(4):324-32
pubmed: 27300254
Am Fam Physician. 2017 Jul 15;96(2):101-107
pubmed: 28762712
Drugs Aging. 2015 Mar;32(3):251-60
pubmed: 25732405